Melanoma Clinical Trial

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Summary

This is a prospective multicenter, matched case-control study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with AU-011 and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.

View Full Description

Full Description

Up to approximately 45 patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the Investigator are planned to be enrolled.

View Eligibility Criteria

Eligibility Criteria

Have per the investigator's expert clinical judgment, a clinical diagnosis of primary indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic examination, fundus photography and conventional ocular ultrasound.

Study is for people with:

Melanoma

Estimated Enrollment:

2

Study ID:

NCT05266430

Recruitment Status:

Terminated

Sponsor:

Aura Biosciences

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Associated Retinal Consultants, P.C.
Royal Oak Michigan, 48073, United States
Oregon Health & Science University Casey Eye Institute
Portland Oregon, 97239, United States
Retina Consultants of Carolina, PA
Greenville South Carolina, 29605, United States
St. Thomas Health/Tennessee Retina, P.C.
Nashville Tennessee, 37203, United States
Retina Consultants of Texas
Bellaire Texas, 77401, United States
Texas Retina Associates
Dallas Texas, 75231, United States
University of Wisconsin Dept of Ophthalmology & Visual Sciences
Madison Wisconsin, 53705, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

2

Study ID:

NCT05266430

Recruitment Status:

Terminated

Sponsor:


Aura Biosciences

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.